

## Changing of the guard at *Depression and Anxiety*

Peter P. Roy-Byrne MD | Murray B. Stein MD, MPH

We have decided to write this editorial together, rather than drafting separate “farewell” and “hello” commentaries. This reflects not just a longstanding history of scientific and editorial collaboration between the two of us, but a belief in the importance of sharing and integration in science—the Japanese Proverb that “none of us is as smart as all of us.”

In truth, the two of us began the task of reinvigorating *Depression and Anxiety* in January of 2008, Peter Roy-Byrne as Editor-In-Chief (EIC) and Murray Stein as Deputy Editor for Anxiety. Along with Myrna Weissman as Deputy Editor for Depression, we set about the task of improving not just the scientific quality of the journal (measurable, at least to some extent, by the impact factor [IF]) but its relevance for practicing clinicians. Dr. Stein departed from his role in 2013 with things well on their way to success and now returns as the incoming EIC. Sabine Wilhelm and Rudolf Uher played key roles as Associate Editors for several years, as did Naomi Simon who will continue as one of our Deputy Editors. Dr. Weissman continued in her position to the present time and provided invaluable guidance and expertise. Over the past decade the IF rose from 1.7 to 5.0.

Likely reflecting the IF rise, was an increasing focus on publishing articles dealing with treatment, both pharmacologic and psychological/behavioral; review papers that offered an up to date snapshot of key areas in the field; and commentaries from experts on important and cutting edge topics. Our papers in the burgeoning fields of genetics and neuroimaging were chosen in part on the basis of their connection with clinical issues, in some way expanding a clinician’s understanding of the field by linking to illness outcomes, risk prediction, or treatment response.

Our affiliation with the Anxiety and Depression Association of America (ADAA), began shortly before we took over, has continued

and has grown during this time, allowing us to publish important papers based on presentations at the organization’s annual meeting, the Scientific Research Symposium, and superb papers that had won or ranked highly in the Donald F. Klein Young Investigator Awards. This strong link between ADAA and *Depression and Anxiety* provides the journal with a solid grounding to clinical relevance and to its research, academic, and clinical contributor and readership base.

We would like to take this opportunity to thank our Editorial Board members and our reviewers (many of whom are on our Editorial Board) for the important jobs they do in ensuring that *Depression and Anxiety* publishes exemplary content. We welcome our three Deputy Editors, Pim Cuijpers PhD, Andrew Nierenberg MD, and Naomi Simon MD to the fold, and express our appreciation for their willingness to take on these critical governance positions within the journal.

As we move into this era of new editorial leadership, we intend to become even more particular in the papers we publish. We will continue to maintain our focus on publishing exemplary science that has something to offer to clinicians. This would include translational science that incrementally advances our understanding of depressive (including bipolar) and anxiety (including obsessive-compulsive and trauma-related) disorders and their treatment. It would also include clinical trials that offer promise, even if not immediate, for the development of new therapeutics. Epidemiological studies will also be welcomed, though the bar will be high for demonstrating not only novelty of results (or important replications), but also clinical and/or public health relevance. We will continue to publish informative neuroimaging and genetic studies, though our standard for required sample sizes and/or within-paper replications will be rigorous. All in all, we expect these efforts to result in a journal that will be even more highly cited and more highly read than ever.